Please login to the form below

Not currently logged in

TGN1412 trial protocol in line, says MHRA

UK regulators have indicated that a clinical trial, which left six male volunteers in hospital, was carried out ìaccording to the agreed protocolî

UK regulators have indicated that a clinical trial, which left six male volunteers in hospital, was carried out ìaccording to the agreed protocolî.

The phase I safety trial of the drug, TGN 1412, a monoclonal antibody being developed to treat conditions including rheumatoid arthritis and leukaemia, was run by contract research organisation Parexel on behalf of German pharma company TeGenero AG.

The Medicines and Healthcare products Regulatory Agency (MHRA) said it had found no evidence to suggest that the drug had been contaminated or improperly manufactured.

ìThere are still further tests planned and until these are complete we cannot be firm about our conclusions,î said MHRA chief executive, Professor Kent Woods. ìHowever, if these findings were to be confirmed, it would indicate that this product showed a pharmacological effect in man which was not seen in pre-clinical tests in animals at much higher doses.î

He added that Health Secretary, Patricia Hewitt, has agreed to establish an international expert group to examine the trial.

Meanwhile, the lawyer representing four of the volunteers who fell ill has criticised Parexel and TeGenero for their response to his request for information about the tests.

Martin Day, of Leigh Day Solicitors, told the BBC that despite his writing nine times over the last few weeks to Parexel and TeGenero, one firm had refused ìpoint blankî to meet him, while the other had simply not responded.

He said he would go through the courts to force them to divulge the information if they were not forthcoming.

30th September 2008


COVID-19 Updates and Daily News

Featured jobs


Add my company
Graphite Digital

Graphite is a digital agency which partners with globally respected healthcare organisations to create powerful digital experiences. We help our...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...